Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
YBX1	rs10493112	AC + CC	abiraterone	efficacy	yes	this was most significant in "high risk" patients where "carriers of the AA genotype had a median time to progression of 4 months compared to 17 months observed for patients with the C allele genotype" in all abiraterone patients AA had TTP of 8 months and AC+CC had 17 months. This was not significant in the enzalutamide patients.	Genotypes AC + CC is associated with increased clinical benefit to abiraterone in men with Prostatic Neoplasms as compared to genotype AA.	32787509	1451262164
YBX1	rs323719	A	bevacizumab	efficacy	no	Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 482 tests (uncorrected p-value = 0.009).	Allele A is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	24070809	1184165271
YBX1	rs323720	C	bevacizumab	efficacy	no	Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 482 tests (uncorrected p-value = 0.014).	Allele C is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele T.	24070809	1184165564